Home/Annexon/Ted Yednock, PhD

TY

Ted Yednock, PhD

EVP & Chief Innovation Officer

Therapeutic Areas

Autoimmune Neurodegenerative Ophthalmic

Annexon Pipeline

Drug	Indication	Phase
ANX005	Guillain-Barré Syndrome (GBS)	Phase 3
ANX007	Geographic Atrophy (GA)	Phase 3
ANX009	Autoimmune Diseases (e.g., Lupus Nephritis)	Phase 1b/2a
ANX1502	Complement-Mediated Diseases	Phase 1

Leadership Team at Annexon

Douglas Love, Esq.

President & Chief Executive Officer

Jamie Dananberg, M.D.

EVP & Chief Medical Officer

Rick Artis, PhD

Chief Scientific Officer

EVP & Chief Financial Officer

Michael Overdorf, MBA

EVP & Chief Business Officer

Thomas G. Wiggans

Ben Barres, MD, PhD

Scientific Co-Founder

Arnon Rosenthal, PhD

View full Annexon profile